Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14900568 | 0.90 | RORC (0.39) | CHRM3 | |
| SCHEMBL14900454 | 0.82 | GRM2 (0.45) | MMEACE | |
| SCHEMBL16939237 | 0.80 | CHRM3 (0.36) | MMECHRM3FASNFFAR4ACE | |
| SCHEMBL16939705 | 0.78 | FASN (0.35) | MMEFASNFFAR4ACE | |
| SCHEMBL16939243 | 0.78 | GRM2 (0.44) | MMECHRM3 | |
| SCHEMBL16930524 | 0.78 | USP30 (0.36) | MMECHRM3FASNFFAR4ACE | |
| SCHEMBL16930525 | 0.78 | USP30 (0.36) | MMECHRM3FASNFFAR4ACE | |
| SCHEMBL14900495 | 0.78 | HCRTR1 (0.41) | — | |
| SCHEMBL16939247 | 0.77 | MME (0.37) | MMEFASNFFAR4 | |
| SCHEMBL16939708 | 0.76 | MME (0.36) | MMEFASNFFAR4ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9884807-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9872855-B2 | (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9868698-B2 | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170355665-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170088508-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9533962-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9433598-B2 | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | MME 1/4885CHRM3 1384/4885FASN 2647/4885 |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CHRM3 1093/4885FASN 4503/4885 |
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | MME 1/4885CHRM3 1141/4885FASN 3640/4885 |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | MME 1/4885CHRM3 1384/4885FASN 2647/4885 |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CHRM3 1093/4885FASN 4503/4885 |
| US-20170088508-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | MME 1/4885CHRM3 1324/4885FASN 2212/4885 |
| US-20170355665-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | MME 1/4885CHRM3 1324/4885FASN 2212/4885 |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | MME 1/4885CHRM3 1324/4885FASN 2212/4885 |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885CHRM3 1141/4885FASN 3640/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885CHRM3 1141/4885FASN 3640/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | MME 1/4885CHRM3 1421/4885FASN 2519/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885CHRM3 1141/4885FASN 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.